Surrozen, Inc./DE Income (Loss) from Continuing Operations before Income Taxes, Domestic
Surrozen, Inc./DE (SRZN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$241.98 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-23
- Surrozen, Inc./DE income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$241.98M.
- Surrozen, Inc./DE income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$63.53M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$241.98M 10-K · filed 2026-03-23 |
| 2024-12-31 | -$63.53M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |